Oragenics (NYSE:OGEN) Earns Sell Rating from Analysts at StockNews.com

StockNews.com assumed coverage on shares of Oragenics (NYSE:OGEN) in a research note issued to investors on Monday morning. The brokerage issued a sell rating on the stock.

Oragenics Trading Down 4.7 %

OGEN opened at $0.43 on Monday. The business has a 50 day moving average of $0.33 and a 200-day moving average of $0.70. The stock has a market capitalization of $5.28 million, a price-to-earnings ratio of -0.06 and a beta of 0.43. Oragenics has a 1-year low of $0.25 and a 1-year high of $7.74.

About Oragenics

Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.